Lecanemab is currently in clinical development for the treatment of early Alzheimer’s disease (AD). AD is a progressive neurological disease which is caused by loss of function and death of neurones in the brain. It is the most common type of dementia.
Lecanemab for treating early Alzheimer's disease
Lecanemab is currently in clinical development for the treatment of early Alzheimer’s disease (AD). AD is a progressive neurological disease which is caused by loss of function and death of neurones in the brain. It is the most common type of dementia.
Interventions:
Lecanemab (BAN2401)
Indications:
Alzheimer's disease
Therapeutic Areas:
Neurology
Year:
2021